A female patient taking tirzepatide (Zepbound) 5 mg subcutaneously weekly has constipation and has lost 16 lb; how should the constipation be managed and when is it appropriate to increase the tirzepatide dose?

Management of Tirzepatide-Induced Constipation and Dose Escalation

Continue tirzepatide at 5 mg weekly while aggressively managing constipation with osmotic and stimulant laxatives, and delay dose escalation until bowel function normalizes for at least 2-4 weeks. 1

Constipation Management Strategy

The constipation is a predictable, dose-dependent gastrointestinal side effect of tirzepatide that occurs most commonly during dose escalation 1. Your patient's 16-pound weight loss indicates excellent therapeutic response, making medication discontinuation unnecessary.

Immediate Interventions

Start with combination laxative therapy:

• Polyethylene glycol (PEG) 17 g daily as first-line osmotic laxative 2
• Add bisacodyl 10-15 mg daily if inadequate response to PEG alone, titrating to achieve one non-forced bowel movement every 1-2 days 3
• If these fail, add lactulose 30-60 mL twice daily or magnesium hydroxide 30-60 mL daily 4, 2

The 2023 AGA-ACG guidelines specifically recommend PEG as first-line therapy with proven durability over 6 months, with stimulant laxatives added for inadequate response 2. The 2025 AACE consensus emphasizes that slow dose up-titration is vital in mitigating GI side effects 1.

Lifestyle Modifications

Counsel the patient to:

• Increase fluid intake substantially (essential when using fiber or osmotic laxatives) 3
• Avoid fatty or spicy foods that exacerbate GI symptoms 1
• Eat smaller, more frequent meals rather than eating past fullness 1
• Monitor which specific foods worsen symptoms 1

Rule Out Complications

Before escalating therapy, exclude fecal impaction (especially if any diarrhea is present, suggesting overflow) and mechanical obstruction through physical examination 3. While rare, tirzepatide has been associated with severe constipation and small bowel obstruction in case reports 5, 6.

Dose Escalation Timing

Do not increase tirzepatide dose until:

1. Constipation is controlled with regular bowel movements (at least every 1-2 days) for 2-4 weeks
2. The patient tolerates current laxative regimen without significant side effects
3. No evidence of impaction or obstruction exists

The 2025 AACE guidelines explicitly state that tirzepatide is "titrated up monthly from a starting dose of 2.5 mg weekly to a maximum dose of 15 mg weekly" 1, but this assumes adequate tolerance. Gastrointestinal side effects occur most commonly during dose escalation 1, so rushing escalation while constipation persists will likely worsen symptoms and risk treatment discontinuation.

When to Consider Dose Escalation

Once constipation is controlled, you can consider increasing to 10 mg weekly if:

• Weight loss has plateaued (though 16 pounds suggests ongoing response)
• Additional metabolic benefits are needed
• The patient has maintained stable bowel function on laxatives for at least one month

The SURMOUNT trials showed dose-dependent weight loss: 12.8% at 10 mg versus 14.7% at 15 mg in patients with diabetes, and even greater reductions in non-diabetic patients 1. However, maintaining therapy is more important than maximizing dose—the SURMOUNT-MAINTAIN trial demonstrated that continuing treatment at any effective dose prevents weight regain 7.

Alternative Considerations

If conventional laxatives fail, consider:

• Prucalopride 1-2 mg daily (5-HT4 agonist prokinetic) 4, 2
• Linaclotide 145-290 mcg daily (intestinal secretagogue) 2
• Elobixibat 5-10 mg daily (ileal bile acid transporter inhibitor)—a 2026 case report showed dramatic improvement in tirzepatide-induced severe constipation resistant to conventional laxatives 8

Critical Pitfalls to Avoid

1. Do not escalate dose while constipation is uncontrolled—this risks treatment discontinuation and loss of metabolic benefits 1
2. Do not use bulk-forming fiber without adequate hydration—this can worsen constipation 3
3. Do not assume constipation will spontaneously resolve—it requires active management 1
4. Monitor for dehydration and renal impairment if vomiting or diarrhea develops 1
5. Watch for gallbladder disease—tirzepatide increases this risk with rapid weight loss 9, 1

The evidence strongly supports that successful long-term obesity management requires ongoing therapy 7, so prioritizing tolerability over aggressive dose escalation will optimize this patient's long-term outcomes.